Unfortunately, early results presented at the meeting “The Promise of Interleukin-2 Therapy” in Paris 2019 indicated that patients treated with IL-2 may show increased decline of C-peptide, cautioning that significant challenges remain to use IL-2 in the clinic for T1D. Here, IL2 is linked to type 1 diabetes mellitus.